News Alert

25 States File Joint Briefs Backing HHS and HRSA in 340B Contract Pharmacy Cases

Connecticut Attorney General William Tong (D) led the coalition of states backing the federal government in 340B contract pharmacy cases before federal appeals courts.

Twenty-five states are backing the federal government in litigation before two federal appeals courts over drug manufacturers’ denials of 340B pricing when covered entities use contract pharmacies.

Please Login or Become a Paid Subscriber

Read More »

News Alert

HRSA Refers Boehringer Ingelheim to HHS Inspector General over its 340B Contract Pharmacy Policy

HRSA has referred Boehringer Ingelheim to the HHS Inspector General for possible imposition of civil monetary penalties over BI's conditions on 340B pricing when hospitals use contract pharmacies.

The U.S. Health Resources and Services Administration (HRSA) today turned the screws tighter on Boehringer Ingelheim (BI) over its “continued failure to provide the 340B price to covered entities utilizing contract pharmacies.”

Please Login or Become

Read More »

News Alert

Johnson & Johnson Becomes the 16th Drug Manufacturer to Restrict 340B Contract Pharmacy

Johnson & Johnson is the 16th drug manufacturer to impose conditions on 340B pricing when hospitals use contract pharmacies.

Drug manufacturer Johnson & Johnson this afternoon announced conditions on 340B sales on 29 products—including several of its top-selling drugs—when hospitals use contract pharmacies.

Please Login or Become a Paid Subscriber to View this Content

Read More »

News Alert

Exclusive: Leading Health Center Organization Calls Gilead’s New 340B Contract Pharmacy Restrictions “Unconscionable”

NACHC called Gilead's 340B pricing conditions on Vosevi and three of its other hepatitis C drugs "the latest example of corporate greed from a pharmaceutical company."

The National Association of Community Health Centers (NACHC) told drug manufacturer Gilead this morning its new conditions on 340B contract pharmacy pricing on its branded hepatitis C treatments are “unconscionable,” “appalling,” “wrongheaded,” and “the latest example of corporate greed from

Read More »

News Alert

HRSA Starts Contacting Hospitals Forced Out of 340B During Pandemic About Possible Reinstatement

HRSA began contacting hospitals today about possible reinstatement in 340B if their termination was due to their DSH adjustment percentage falling as a result of the hospital's COVID-19 response.

The U.S. Health Resources and Services Administration (HRSA) this morning began contacting hospitals forced to leave the 340B program during the COVID-19 pandemic about possible reinstatement to 340B under a new federal law.

Please Login or

Read More »

News Alert

Gilead Announces 340B Contract Pharmacy Restrictions that Apply to Hospital and Grantee Entities

Gilead is requiring 340B covered entities to supply claims data for its branded hepatitis C products to be able to continue to be eligible for bill to / ship to orders for multiple contract pharmacies.

Gilead late yesterday imposed conditions on 340B pricing on its branded hepatitis C treatments when covered entities use contract pharmacies.

Please Login or Become a Paid Subscriber to View this Content

Read More »

News Alert

U.S. Senate OK’s Limited Relief for Hospitals Forced Out of 340B Due to COVID-19

The U.S. Senate gave final passage last night to legislation to help some hospitals forced out of the 340B program during the COVID-19 pandemic.

The U.S. Senate last night passed a $1.5 trillion federal appropriations bill with language to help some hospitals forced out of the 340B program during the COVID-19 pandemic.

Please Login or Become a Paid Subscriber to

Read More »

News Alert

Congress Is Close to Passing a Spending Bill that Likely Will Address Hospitals’ Loss of 340B Eligibility During Pandemic

Congress as soon as Friday could pass legislation addressing hospitals’ loss of eligibility for 340B drug discounts due to COVID-19-related changes in payer mix.

Legislation addressing hospitals’ loss of eligibility for 340B drug discounts due to COVID-19-related changes in payer mix could reach President Biden before Friday at midnight.

Please Login or Become a Paid Subscriber to View this Content

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
×

*Sign up for news summaries and alerts from 340B Report